BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LY4052031 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LY4052031\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06465069-2604@assetmemo.bio
DTSTAMP:20261121T005450Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:LY4052031: Phase 1 readout est. (NCT06465069)
DESCRIPTION:LY4052031\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy of LY4052031 in Participants With Advanced or Metastatic Urothelial Can
 cer or Other Solid Tumors\nEstimated primary completion: May 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ly4052031#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06465069
URL:https://assetmemo.bio/drug/ly4052031#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
